Adding savolitinib to osimertinib beneficial for certain pretreated lung cancer patients - EurekAlert

Adding savolitinib to osimertinib beneficial for certain pretreated lung cancer patients  EurekAlert

Adding the investigational MET inhibitor savolitinib to the EGFR inhibitor osimertinib (Tagrisso) yielded clinical responses in patients who had EGFR-mutant ...



Comments

Popular posts from this blog

Oncology: The disease, dynamics & challenges of market research

A Review of the Etiology and Epidemiology of Bladder Cancer: All ...

Lung Cancer Among People Who Never Smoked